

## CLAIMS

- 1 A complex comprising an HLA class I molecule or fragment thereof,  
which HLA class I molecule or fragment thereof <sup>that?</sup> comprises a T cell binding  
portion, and attaching means for selectively attaching said HLA class I molecule  
or fragment thereof to a target cell.
- 2 A complex as claimed in claim 1, wherein said attaching means comprises  
a linking polypeptide with high specific affinity for a target cell specific molecule  
on the surface of the target cell.
- 3 A complex as claimed in claim 2, wherein said linking polypeptide  
comprises an antibody, preferably a monoclonal antibody, raised against said  
target cell specific molecule.
- 4 A complex as claimed in claim 2 ~~or claim 3~~, wherein said linking  
polypeptide is adapted to be attached directly to said HLA class I molecule or  
fragment thereof.
- 5 A complex as claimed in claim 2 ~~or claim 3~~, wherein said attaching means  
further comprises a coupling system for coupling said linking polypeptide to said
- not right!

HLA class I molecule or fragment thereof.

6 A complex as claimed in claim 5, wherein said coupling system comprises  
a two- or three-step chain of well-characterised paired small molecules, which  
5 chain is joined to the linking polypeptide and the HLA class I molecule so as to  
form a stable bridge between the two.

7 A complex as claimed in claim 6, characterised in that said chain  
comprises biotin and avidin/streptavidin.

8 A complex as claimed in claim 6, characterised in that said chain  
comprises calmodulin and calmodulin binding peptide.

9 A complex as claimed in <sup>Claim 1</sup> ~~any preceding claim~~, which complex comprises  
15 a recombinant protein, which recombinant protein includes a moiety comprising  
said HLA class I molecule or fragment thereof, and a moiety comprising said  
attaching means.

10 A complex as claimed in <sup>Claim 1</sup> ~~any preceding claim~~, characterised in that said  
20 HLA class I molecule or fragment thereof binds or is attached to a recognition  
peptide, which recognition peptide is arranged to be presented by said HLA class

008211 5864260

A

I molecule or fragment thereof for T cell recognition.

9 11 A complex as claimed in <sup>claim 1</sup> ~~any preceding claim~~, characterised in that said target cell is a type of cell the presence of which is undesirable in a patient, such as a tumour cell or a diseased, foreign or malignant cell such as a cancer cell, a leukaemia cell, a cell infected with the HIV virus or with any other parasite, bacterium, microbe or virus, or a cell responsible for detrimental activity in autoimmune disease.

10 12 A complex as claimed in claim 11 ~~appended to claim 10~~, wherein <sup>there is a</sup> ~~said~~ recognition peptide <sup>that</sup> comprises a peptide which has a strong cytotoxic T cell response or which is capable of inducing a powerful immune response.

13 A complex as claimed in claim 11 ~~appended to claim 10, or claim 12~~, <sup>there is a</sup> ~~wherein said~~ recognition peptide <sup>that</sup> comprises a viral or microbial peptide, such as an influenza virus peptide, a measles virus peptide, an Epstein-Barr virus peptide, in particular an Epstein-Barr virus peptide comprising the RAKFFQLL epitope of the lytic protein BZLF1, a Cytomegalovirus peptide, or a tetanus toxoid peptide.

20 14 A complex as claimed in <sup>claim 11</sup> ~~any of claims 11-13~~, wherein the allotype of said

008211 58642/50

SUB 3

a

a

a

HLA class I molecule or fragment thereof is different from the allotype of the HLA class I molecules of the patient, so that an alloreactive response can additionally or alternatively be triggered against said target cell.

9 5 15 A complex as claimed in <sup>claim 1</sup> ~~any of claims 1-10~~, wherein said target cell is an antigen presenting cell.

9 16 A complex as claimed in claim 15 <sup>there is</sup> ~~appended to claim 10~~, wherein said recognition peptide comprises a tumour specific peptide, or a viral peptide, or a bacterial peptide, or a parasitic peptide, or any peptide which is exclusively or  
10 characteristically presented by HLA class I molecules on the surface of diseased or malignant cells, or virally, bacterially, parasitically or microbially infected cells, or foreign cells the presence of which is undesirable in a patient.

a 17 A complex as claimed in <sup>claim 1</sup> ~~any preceding claim~~, wherein said target cell is  
15 a culture cell.

a 18 A complex as claimed in <sup>claim 1</sup> ~~any of claims 1-10~~, wherein said target cell is a cell in the body of a patient.

9 20 19 A method for attaching the complex of <sup>claim 1</sup> ~~any of claims 1-10~~ to said target cell, comprising the step of introducing to said target cell said HLA class I

09724985 11300

molecule or fragment thereof and said attaching means.

20 Use of the complex of claim 15 ~~or claim 16~~ in the in vivo or ex vivo amplification of cytotoxic T cells with specificity for said recognition peptide.

21 A method for producing or enhancing an immunological response against a target cell, comprising the step of attaching the complex of <sup>claim 1</sup> ~~any of claims 1-18~~ to said target cell ~~in accordance with the method of claim 19.~~

<sup>A2</sup> by introducing

22 A method for immunising a patient against a disease or condition which is characterised by the presence in the patient's body of cells displaying said recognition peptide on the surface thereof; such as a tumour, or a malignant or auto-immune disease such as cancer or leukaemia, an infectious disease such as a viral infection such as HIV infection, a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria; comprising the step of administering to said patient an effective amount of the complex of claim 15 ~~or~~

~~claim 16.~~

23 A pharmaceutical composition for use in immunising a patient against a disease or condition which is characterised by the presence in the body of the patient of diseased, malignant or foreign cells; such as a tumour, or a malignant

008211 5864260

or auto-immune disease such as cancer or leukaemia, or an infectious disease such as a viral infection such as HIV infection, or a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria; said pharmaceutical composition comprising a complex as claimed in claim 15 or claim 16 and an appropriate excipient or carrier.

24 Use of the complex of claim 15 or ~~claim 16~~ in the preparation of a medicament for use in immunising a patient against a disease or condition which is characterised by the presence in the patient's body of cells displaying said recognition peptide on the surface thereof; such as a tumour, or a malignant or auto-immune disease such as cancer or leukaemia, an infectious disease such as a viral infection such as HIV infection, a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria.

25 A method for the treatment of a disease or condition such as a tumour, or a malignant or auto-immune disease such as cancer or leukaemia, an infectious disease such as a viral infection such as HIV infection, a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria, comprising the step of administering to a patient in need thereof an effective amount of the complex of <sup>claim 11</sup> ~~any of claims 11-14~~

26 A pharmaceutical composition for use in the treatment of a disease or condition characterised by the presence in a patient of diseased, foreign or malignant cells; such as a tumour, or a malignant or auto-immune disease such as cancer or leukaemia, or an infectious disease such as a viral infection such as HIV infection, or a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria; said pharmaceutical composition comprising a complex as claimed in <sup>claim 11</sup> ~~any of claims 11-14~~ and an appropriate excipient or carrier.

10 27 Use of the complex of <sup>claim 11</sup> ~~any of claims 11-14~~ in the preparation of a medicament for the treatment of a tumour, or a malignant or auto-immune disease such as cancer or leukaemia, or an infectious disease such as a viral infection such as HIV infection, or a bacterial or microbial infection such as tuberculosis, or a parasitic infection such as malaria.

15

28 A pharmaceutical pack or kit comprising one or more containers containing one or more of the pharmaceutical compositions claimed in claim 23 ~~or claim 26~~ and written instructions for the administration of said composition or compositions to a patient.

20

008217" 58642260

D

Sub  
C2add  
C3